Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042063 | 0.89 | HDAC3 (0.51) | HDAC3HDAC2HDAC1PLD1KCNH2 | |
| Hydrochloric Acid SCHEMBL4426185 | 0.87 | HDAC3 (0.50) | HDAC3HDAC2HDAC1PLD1KCNH2 | |
| SCHEMBL25666898 | 0.84 | MAPT (0.44) | HDAC3HDAC2KDM4EALDH1A1KMO | |
| SCHEMBL14658665 | 0.83 | MAPT (0.45) | HDAC3HDAC2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL30855580 | 0.83 | MAPT (0.45) | HDAC3HDAC2KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL29115584 | 0.81 | HDAC3 (0.54) | HDAC3HDAC2HDAC1KCNH2HPGDS | |
| SCHEMBL1831306 | 0.81 | HDAC3 (0.48) | HDAC3HDAC2HDAC1KDM4EMEN1 | |
| SCHEMBL30542912 | 0.81 | HDAC3 (0.54) | HDAC3HDAC2HDAC1KCNH2HPGDS | |
| Hydrochloric Acid SCHEMBL4427145 | 0.80 | KMT2A (0.48) | HDAC3HDAC2HDAC1KDM4EMEN1 | |
| SCHEMBL877503 | 0.80 | HRH3 (0.43) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242900-A1 | COACERVATE-FORMING REAGENTS AND METHODS | PARTITIONBIO LTD (GB) | 2025-11-27 | — | — | WO | claimed |
| WO-2025242900-A1 | COACERVATE-FORMING REAGENTS AND METHODS | PARTITIONBIO LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-115605488-A | Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | GILEAD SCIENCES, INC. | 2021-11-18 | — | — | US | disclosed |
| WO-2021226262-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2012027322-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, HIPK2 | HDAC3 1478/4885HDAC2 1769/4885HDAC1 1386/4885 |
| US-20210355140-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | HDAC3 1478/4885HDAC2 1769/4885HDAC1 1386/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | HDAC3 1478/4885HDAC2 1769/4885HDAC1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.